1. Home
  2. ALT vs BRW Comparison

ALT vs BRW Comparison

Compare ALT & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • BRW
  • Stock Information
  • Founded
  • ALT 1997
  • BRW 1987
  • Country
  • ALT United States
  • BRW United States
  • Employees
  • ALT N/A
  • BRW N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • BRW Trusts Except Educational Religious and Charitable
  • Sector
  • ALT Health Care
  • BRW Finance
  • Exchange
  • ALT Nasdaq
  • BRW Nasdaq
  • Market Cap
  • ALT 292.0M
  • BRW 355.1M
  • IPO Year
  • ALT N/A
  • BRW N/A
  • Fundamental
  • Price
  • ALT $3.83
  • BRW $8.31
  • Analyst Decision
  • ALT Strong Buy
  • BRW
  • Analyst Count
  • ALT 6
  • BRW 0
  • Target Price
  • ALT $17.40
  • BRW N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • BRW 222.1K
  • Earning Date
  • ALT 08-12-2025
  • BRW 01-01-0001
  • Dividend Yield
  • ALT N/A
  • BRW 15.59%
  • EPS Growth
  • ALT N/A
  • BRW N/A
  • EPS
  • ALT N/A
  • BRW N/A
  • Revenue
  • ALT $20,000.00
  • BRW N/A
  • Revenue This Year
  • ALT N/A
  • BRW N/A
  • Revenue Next Year
  • ALT $761,880.20
  • BRW N/A
  • P/E Ratio
  • ALT N/A
  • BRW N/A
  • Revenue Growth
  • ALT N/A
  • BRW N/A
  • 52 Week Low
  • ALT $2.90
  • BRW $7.15
  • 52 Week High
  • ALT $11.16
  • BRW $8.30
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • BRW 50.04
  • Support Level
  • ALT $3.35
  • BRW $8.24
  • Resistance Level
  • ALT $3.66
  • BRW $8.46
  • Average True Range (ATR)
  • ALT 0.19
  • BRW 0.08
  • MACD
  • ALT 0.07
  • BRW -0.01
  • Stochastic Oscillator
  • ALT 86.18
  • BRW 31.82

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

Share on Social Networks: